Changeflow GovPing Pharma & Drug Safety Engineered Fc Constructs Patent Application - M...
Routine Notice Added Final

Engineered Fc Constructs Patent Application - Momenta Pharmaceuticals

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Biotech (C12N)
Published March 25th, 2026
Detected April 1st, 2026
Email

Summary

The European Patent Office published patent application EP3464376A1 for Momenta Pharmaceuticals, Inc. on March 25, 2026. The application covers compositions and methods related to engineered Fc constructs with applications in immunology and therapeutic development. The publication designates 38 European member states.

What changed

The EPO published patent application EP3464376A1 filed by Momenta Pharmaceuticals, Inc. for engineered Fc constructs. The application claims priority to immunology-related compositions and methods (IPC classifications C07K 16/00, C12N 9/00, A61K 39/395). The designated states cover major European markets including DE, FR, GB, IT, ES, NL, BE, CH, SE, and 30 others.

This is a patent publication notice with no immediate compliance obligations. Pharmaceutical and biotechnology companies developing Fc-engineered therapeutics should review the claims for potential freedom-to-operate concerns. Patent prosecution will continue through standard EPO procedures; the publication does not grant patent rights but establishes prior art as of the filing date.

What to do next

  1. Review patent claims for freedom-to-operate analysis if developing Fc construct therapeutics
  2. Monitor EPO prosecution of EP3464376A1 for claim scope and grant status

Source document (simplified)

← EPO Patent Bulletin

COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS

Publication EP3464376A1 Kind: A1 Mar 25, 2026

Applicants

Momenta Pharmaceuticals, Inc.

Inventors

LANSING, Jonathan C., BOSQUES, Carlos J., ORTIZ, Daniel

IPC Classifications

C07K 16/00 20060101AFI20260213BHEP C07K 16/46 20060101ALI20260213BHEP C12N 9/00 20060101ALI20260213BHEP C12N 9/96 20060101ALI20260213BHEP G01N 33/53 20060101ALI20260213BHEP A61P 37/04 20060101ALI20260213BHEP A61P 29/00 20060101ALI20260213BHEP A61P 37/00 20060101ALI20260213BHEP A61P 37/02 20060101ALI20260213BHEP A61P 37/06 20060101ALI20260213BHEP A61P 43/00 20060101ALI20260213BHEP A61K 39/395 20060101ALI20260213BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP3464376A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Biotechnology companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent prosecution Therapeutic Fc construct development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Intellectual Property
Topics
Pharmaceuticals Biotechnology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.